Claims data reveal larger hemoglobin A1c decreases in people with type 2 diabetes who use continuous glucose monitoring and semaglutide compared with semaglutide alone. Study Design: Using US health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback